XERS Stock Forecast & Price Target

Xeris Biopharma Holdings Inc. has demonstrated significant growth in key product sales, with Recorlev revenues increasing by 131% year-over-year to $22.6 million in 4Q24, and Gvoke sales rising by 25% to $23.3 million during the same period. The company also reported a substantial increase in new prescriptions, with a 123% growth in new starts for its products in 4Q24 compared to the prior year, indicating a widening prescriber base. Furthermore, a moderate increase in operational expenditures, guided to rise by mid-to-high single digits, suggests a stronger operating leverage and potential for improved profitability moving forward.

Xeris Biopharma Holdings Inc. reported a narrower net loss per share of ($0.03) in the fourth quarter, outperforming estimates, yet it faces significant challenges due to potential R&D and FDA setbacks and increasing competition from generic drug makers. While the company provided revenue guidance for 2025 that suggests growth, the anticipated range of $255-$275 million only marginally exceeds prior estimates and raises concerns about sustaining momentum. Additionally, with a GAAP net income loss of ($5.1 million) and pressures from new market entries, the fundamental outlook remains bleak despite some positive quarterly performance metrics.